Medical Professionals Reference (MPR)ADA: Once-Daily Orforglipron Linked to Significant Weight Reduction

By week 36, 46 to 75% of patients on orforglipron had lost at least 10% of their body weight.

Orforglipron, a once-daily oral GLP-1 receptor agonist, caused adults with obesity or overweight to lose weight in a way that was clinically significant, according to a study that was released online in the New England Journal of Medicine on June 23 to coincide with the American Diabetes Association’s annual meeting, which was held from June 23 to 26 in San Diego.

Key Points:

• A total of 272 patients were randomly randomized to receive orforglipron once daily for 36 weeks at doses of 12, 24, 36, or 45 mg, or a placebo.
• The mean change from baseline in body weight ranged from −9.4% to −14.7% with orforglipron and was −2.3% with placebo at 36 weeks.
• A weight reduction of at least 10% occurred in 46% to 75% receiving orforglipron and 9% receiving placebo; a weight reduction of at least 15% occurred in 48% and 1% of those receiving orforglipron 45mg and placebo, respectively.

Additonal Points:

• The safety profile was consistent with that of the GLP-1 receptor agonist class.

Conclusion:

• Further studies are needed to establish whether the health benefits seen with injectable GLP-1 receptor agonists are shared by orforglipron.

Endocrinology Latest Posts

• 9 Health Benefits of CashewsNovember 21, 2024
• Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisNovember 21, 2024
• Off-brand Ozempic Leaves 10 Dead, 100 HospitalizedNovember 20, 2024
• Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin: A Multi-database Cohort StudyNovember 11, 2024

Did You Know?
According to the CDC, more than 42% of adults in the United States are obese.